Amnion has amassed significant expertise in free amino ion-releasing molecule discovery and development, including capabilities in creating species specific treatment solutions for even the most advanced health problems. While the company’s current efforts are focused on the development of TAFA400™, its core research and formulation library are available for future product pipeline and/or collaboration opportunities.

TAFA400TM Treatments

In numerous animal studies, TAFA400™ treatments have been consistently shown to promote healing, even in the most difficult-to-treat cases. Why? It comes down to cells.

When cells become unstable through injury or disease and are unable to restore stability through natural biosynthesis, the opportunity to mutate and become dysfunctional is present. Unfortunately, these dysfunctional cells can lead to ailments as common as hot spots or extreme cases of life-threatening conditions. Quoting from the Free Amino Ion Theory authored by Steven R. Schutt, biosynthesis is by definition the process whereby amino acids combine with the nucleic acids within the nuclei sequentially, thus causing unstable nuclei within the cells to go into alignment.  Alignment is stability. Free amino ions bonding to the nucleic acids within the nucleus of unstable cells and/or mutant cells, result in biosynthesis, causing the nucleic acids to align and become stable.  Thus it is possible to cause mutant cells to return to their normal function as programmed by their original DNA coding which is still implanted within their structure. The combining of Triamino™ with chemically pure, pharmaceutical grade Fulvic Acid™ (Carbohydrate Derived Plant Acid) has not only augmented the Triamino™ molecule but has added the benefits of the most effective and totally nontoxic, anti-microbial, anti-viral and anti-fungal agent known to man.

The Triamino™ and Triamino Fulvate™ molecules were invented and developed by Steven R. Schutt. These consist of key pharmaceutical grade, chemically pure amino acids, and carbohydrate-derived fulvic acid compounds. Amino acids are referred to as the ‘building blocks’ of life. These compounds are loosely bound by hydrogen to allow the release of the stabilizing free amino ions into the cell nuclei. The molecular structure is fully biocompatible, non-allergenic, and does not elicit an immune reaction, local or systemic toxicity, or inflammation in animals, and its first-in-class FDA GRAS status is a platform that provides the opportunity to develop many disease-specific cell restoration products, for which there are significant unmet medical needs.

Unique Formulations

The Triamino™ and Triamino Fulvate™ molecules are a perfect platform to generate stable, highly efficacious pH-neutral products, based on the science of cell stabilization.

Antimicrobial Efficacy: The pharmaceutical grade, chemically pure, carbohydrate-derived Fulvic acid is a broad-band antimicrobial, encompassing Gram-positive cocci, Gram-negative bacilli, and yeasts. This inhibition spectrum is not seen with present conventionally prescribed pharmaceutical antibiotics. Recently published clinical trials confirm that fulvic acid was found to be effective against the three strains of recently isolated S. aureus. These antimicrobial and antibacterial properties have been enhanced through molecular engineering by combining the Fulvic acid compound with the highly bioactive Triamino molecule, further extending the benefits of TAFA400™ treatments.

Stability: At neutral pH, TAFA400™ products have shelf lives of twenty four months and beyond. The unique molecular chemistry behind Amnion treatments generates stable, free amino fulvate ions in a bottle.

Key Treatment Benefits

  • TAFA400™ treatments offer multiple delivery methods (inoculation by subcutaneous infusion, intravenous injection, inhalation, oral feeding and direct topical application) and a wide latitude on dosing requirements.
  • TAFA400™ treatments do not anesthetize, relieving discomfort without diminishing sensation.
  • TAFA400™ treatments have extraordinary pain-relieving qualities.
  • TAFA400™ treatments encourage accelerated healing while suppressing the formation of scar tissue.
  • TAFA400™ treatments effectively treat both Gram-Positive and Gram-Negative topical infections.
  • TAFA400™ treatments are not vasodilators, but they similarly stimulate micro-circulation to accelerate the removal of foreign matter from wounds and lesions of all types.
  • TAFA400™ treatments have shown in maximal application no side effects, no toxicity, further supported by complete Lethal Dose (Ld-50) testing.